CURE Pharmaceutical [OTCQB:CURR] and Canopy Growth to Produce CBD Oral Thin Films
June 19 2019 - 7:25AM
CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and
development company, today announced it is collaborating with
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), (“Canopy”) to
develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using
CURE’s patented CUREfilm™ technology for global distribution. This
CUREfilm license gives Canopy a dosage form that is ideal for
administering cannabinoids.
“This collaboration builds on our licensing agreement with
Canopy and accelerates product commercialization,” said Rob
Davidson, CEO of CURE Pharmaceutical. “We will leverage our recent
patented developments in cannabis-based drug delivery, to formulate
an oral thin film product for optimal efficacy and dosing
frequency.”
CURE is registered with the U.S. Drug Enforcement Agency (DEA)
to develop and manufacture cannabis-derived and synthetic
cannabinoid-based products using its CUREfilm technology at its
facility in Oxnard, Calif. With CUREfilm, the delivery of
cannabinoids is easier and more effective as it offers increased
bioavailability, ease and precision of dosing and greater
palatability.
About CURE PharmaceuticalCURE Pharmaceutical is
a vertically integrated drug delivery and development company
committed to improving drug efficacy, safety, and the patient
experience through its proprietary drug dosage forms and delivery
systems. CURE has a full-service cGMP manufacturing facility and is
a pioneering developer and manufacturer of a patented and
proprietary delivery system (CUREfilm™), one of the most advanced
oral thin film on the market today. CURE is developing an array of
products in innovative delivery platforms and partners with biotech
and pharmaceutical companies. CURE has positioned itself to advance
numerous therapeutic categories, including the pharmaceutical
cannabis sector with partnerships in the U.S., Canada, and Israel.
The company's mission is to improve people's lives by redefining
how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its
website at www.curepharma.com.
About Canopy Growth CorporationCanopy Growth is
a world-leading diversified cannabis and hemp company, offering
distinct brands and curated cannabis varieties in dried, oil and
Softgel capsule forms. From product and process innovation to
market execution, Canopy Growth is driven by a passion for
leadership and a commitment to building a world-class cannabis
company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector
names including cannabis icon Snoop Dogg, breeding legends DNA
Genetics and Green House seeds, and Fortune 500 alcohol leader
Constellation Brands, to name but a few. Canopy Growth operates ten
cannabis production sites with over 2.4 million square feet of
production capacity, including over 500,000 square feet of
GMP-certified production space. Canopy Growth has operations in 10
countries across five continents. The Company is proudly dedicated
to educating healthcare practitioners, conducting robust clinical
research, and furthering the public’s understanding of cannabis,
and through its fully owned subsidiary, Canopy Health Innovations,
has devoted millions of dollars toward cutting edge,
commercializable research and IP development. Through partly owned
subsidiary Canopy Rivers Corporation, Canopy Growth is providing
resources and investment to new market entrants and building a
portfolio of stable investments in the sector. From our historic
public listing to our continued international expansion, pride in
advancing shareholder value through leadership is engrained in all
we do at Canopy Growth. For more information
visit www.canopygrowth.com.
This press release contains forward-looking statements that
involve risks and uncertainties. There are important factors that
could cause actual results to differ materially from those in the
forward-looking statements. These factors include, without
limitation, the ability to successfully market our products, the
difficulty in predicting the timing or outcome of other product
research and development efforts, potential product characteristics
and indications, marketing approvals and launches of other
products, the impact of pharmaceutical industry regulation, the
impact of competitive products and pricing, the acceptance and
demand of new pharmaceutical products, the impact of patents and
other proprietary rights held by competitors and other third
parties and the ability to obtain financing on favorable terms. The
forward-looking statements in this press release reflect the
Company's judgment as of the date of this press release. The
Company disclaims any intent or obligation to update these
forward-looking statements. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of our securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
CURE Media Contact: Ashley Ray Olmstead
Williams Communication aray@olmsteadwilliams.com
310-824-9000
Canopy Growth (NASDAQ:CGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Canopy Growth (NASDAQ:CGC)
Historical Stock Chart
From Sep 2023 to Sep 2024